Brief: Epigenomics: Centers For Medicare & Medicaid Services Open NCD Review Process For Epi proColon
02/03/2020 06:24
March 2(Reuters) - EPIGENOMICS AG ECXn.DE :
* SAID ON FRIDAY CENTERS FOR MEDICARE & MEDICAID SERVICES
(CMS)
OPENED NATIONAL COVERAGE DETERMINATION (NCD) REVIEW OF EPI
PROCOLON, EPIGENOMICS' BLOOD TEST FOR COLORECTAL CANCER
SCREENING
* DECISION ON CMS'S REIMBURSEMENT OF EPI PROCOLON MUST BE
MADE
WITHIN MAXIMUM PERIOD OF NINE MONTHS
* POSITIVE CMS REIMBURSEMENT DECISION WOULD REPRESENT MAJOR
BREAKTHROUGH FOR COMPANY IN COMMERCIALIZATION OF EPI PROCOLON IN
US MARKET
Source text for Eikon: urn:newsml:reuters.com:*:nEQ4QYLDza
Further company coverage: ECXn.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns